C

Tactile Systems Technology, Inc. TCMD

NASDAQ
Recommendation
Dividend Power Score
Day's Range
$25.81$26.80
Latest Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
EPS (TTM)
My Lists My Alerts

Company Overview

Tactile Systems Technology, Inc. (NASDAQ: TCMD), commonly known as Tactile Medical, is a U.S.-based medical technology company focused on developing and commercializing medical devices for chronic disease management in the home setting. The company primarily operates in the durable medical equipment and medical device industries, with a concentration on therapies for lymphedema, chronic venous insufficiency, and pulmonary conditions associated with retained secretions. Its core products are designed to support long-term patient care outside of acute clinical environments, with reimbursement support from Medicare, Veterans Affairs programs, and commercial insurers.

The company’s principal revenue drivers include its proprietary pneumatic compression systems and airway clearance devices. Its flagship products include the Flexitouch system for lymphedema treatment, the Entre system for edema management, and the AffloVest system for airway clearance therapy. Tactile Medical primarily serves patients with chronic conditions, healthcare providers, clinics, and integrated delivery networks across the United States. The company differentiates itself through a clinically focused sales model, reimbursement expertise, and direct patient support infrastructure. Founded in 1995 and headquartered in Minnesota, the company evolved from a niche compression therapy provider into a broader chronic disease management platform through internal product development and acquisitions, including the acquisition of AffloVest assets to expand into respiratory therapy.

Business Operations

Tactile Medical operates primarily through a single reportable business focused on medical devices and therapy solutions for chronic conditions treated in home-based settings. Revenue is generated through sales of compression therapy systems and airway clearance products, with a substantial portion supported by third-party reimbursement programs. The company markets and distributes products directly through a nationwide sales organization and clinical support network. While operations are predominantly concentrated in the United States, the company has historically maintained limited international exposure through select distribution relationships.

The company’s major product categories include the Flexitouch, Entre, and AffloVest therapy systems. Tactile Medical controls proprietary pneumatic compression technologies and related therapy protocols designed to improve lymphatic flow and secretion clearance. The company also maintains relationships with healthcare providers, referral networks, and payors that support patient onboarding and reimbursement processing. Its business model combines device sales with patient education, clinical engagement, and long-term therapy adherence support.

Strategic Position & Investments

Tactile Medical’s strategic direction has centered on expanding adoption of home-based chronic care therapies, particularly in lymphedema management and pulmonary health. The company has invested in clinical evidence generation, reimbursement expansion, and sales force growth to increase physician referrals and patient access. Management has also emphasized broadening awareness of chronic swelling disorders and improving earlier diagnosis pathways through provider engagement and educational initiatives.

A notable strategic development was the acquisition of AffloVest, which expanded the company into airway clearance therapy for patients with pulmonary conditions such as bronchiectasis and neuromuscular disorders. Tactile Medical has continued investing in digital patient engagement, operational infrastructure, and market expansion initiatives intended to support long-term growth. Public disclosures and investor materials indicate ongoing emphasis on increasing penetration in underdiagnosed patient populations and strengthening relationships with Medicare and commercial payors. Data regarding material international investment activity remains limited based on available public sources.

Geographic Footprint

Tactile Medical is headquartered in Minnesota, United States, and its commercial operations are primarily concentrated across the United States. The company maintains a nationwide sales and clinical support presence serving physicians, hospitals, outpatient clinics, and home-care patients. Its core market exposure is domestic, particularly within regions with large Medicare populations and established vascular, oncology, and pulmonary treatment networks.

The company’s operational footprint includes distribution, reimbursement support, and clinical service capabilities across multiple U.S. states. International operations appear limited relative to larger multinational medical device manufacturers, though certain products have been distributed outside the U.S. through third-party relationships. Available public filings and company disclosures indicate that the overwhelming majority of revenue is derived from the U.S. market.

Leadership & Governance

Tactile Medical operates under a corporate governance structure led by an executive management team and board of directors with experience in medical technology, healthcare operations, and commercialization. Strategic leadership has focused on expanding reimbursement-supported home therapies, scaling commercial execution, and increasing clinical adoption through evidence-based marketing and provider engagement.

Key executives include:

  • Sheri Dodd – Chief Executive Officer
  • Elaine M. Birkemeyer – Chief Financial Officer
  • Adam L. Jaffe – Chief Operating Officer
  • Brent E. Maupin – General Counsel and Chief Compliance Officer
  • Tom Fanning – Chief Commercial Officer

Leadership communications in public filings and investor presentations emphasize disciplined growth, clinical validation, patient-centered care delivery, and operational efficiency. Governance practices are outlined in company disclosures including annual reports and proxy statements filed with the U.S. Securities and Exchange Commission (SEC).

Data compiled by narrative technology. May contain errors.

Top Tech Stocks
See All »
B
AAPL NASDAQ $349.21
B
MSFT NASDAQ $498.30
B
NVDA NASDAQ $145.98
Top Consumer Staple Stocks
See All »
B
WMT NASDAQ $126.04
B
Top Financial Stocks
See All »
A
B
JPM NYSE $320.22
B
V NYSE $402.25
Top Energy Stocks
See All »
B
CVX NYSE $206.50
B
COP NYSE $134.99
Top Health Care Stocks
See All »
B
LLY NYSE $1,351.12
B
JNJ NYSE $267.14
B
ABBV NYSE $283.54
Top Real Estate Stocks
See All »
B
PLD NYSE $123.36